Freedom Capital Markets Reiterates Buy Rating on Inspire Medical Systems
Freedom Capital Markets maintains its positive outlook on Inspire Medical Systems with a $62 price target, a 38.98% upside from the current price.
Key Points
- Freedom Capital Markets reiterated its buy rating on Inspire Medical Systems with a $62 target on July 1, 2026.
- Freedom Capital Markets's $62 price target implies 38.98% upside from Inspire Medical Systems, Inc.'s ($INSP) current $44.61 share price.
- Shares of Inspire Medical Systems traded near $44.61 on Wednesday, with a market cap of about $1.29 billion and a P/E ratio of 10.14.
- Recent insider activity includes sales by John Rondoni and Shawn McCormick, while analysts have varied ratings with a consensus hold recommendation.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Freedom Capital Markets has reiterated its buy rating on Inspire Medical Systems, Inc. (NYSE:INSP) with a price target of $62. This update was made on July 1, 2026, by analyst Keith Hinton.
Inspire Medical Systems, Inc. Stock Down 27.4%
Shares of NYSE:INSP traded near $44.61 on Wednesday. Inspire Medical Systems has a market cap of approximately $1.29 billion and a P/E ratio of 10.14. The stock's 52-week range is between $38.91 and $147.03, with a 50-day moving average of $45.79 and a 200-day moving average of $71.98. The company maintains a strong current ratio of 6.34 and a quick ratio of 4.35.
$INSP price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
In its latest earnings report, Inspire Medical Systems posted revenue of $915.25 million, reflecting a modest growth of 1.6%. The company's net margin stands at 14.33%, with a return on equity of 18.37%. The next earnings release is scheduled for August 3, 2026.
Insider Buying and Selling at Inspire Medical Systems, Inc.
There has been notable insider activity at Inspire Medical Systems. John Rondoni, Chief Product and Innovation Officer, sold 2,641 shares at an average price of $43.28 on May 15, 2026. Earlier, on May 14, he sold 700 shares at $43.01. On May 8, Shawn McCormick sold 696 shares at $45.31 as part of a planned transaction.
Analysts Set New Price Targets
On July 1, 2026, Freedom Capital Markets reiterated a buy rating for Inspire Medical Systems with a $62 price target. Evercore ISI Group downgraded the stock to hold with a $40 target on June 23, 2026. On May 5, 2026, JP Morgan maintained its hold rating with a $54 target, while Piper Sandler also downgraded to hold with a $55 target. The consensus among analysts is a hold rating, with an average target price of $50.92 based on 12 opinions.
About Inspire Medical Systems
Inspire Medical Systems, Inc. is a healthcare company based in Golden Valley, Minnesota. It specializes in developing minimally invasive solutions for obstructive sleep apnea (OSA). The company's flagship product, the Inspire system, uses neurostimulation technology to treat moderate to severe OSA. Founded in 2007, Inspire Medical Systems continues to innovate in the medical devices industry under the leadership of CEO Timothy P. Herbert.
Bottom Line
Inspire Medical Systems remains a company of interest with its innovative approach to treating sleep apnea. The reiterated buy rating from Freedom Capital Markets suggests confidence in its future prospects. However, investors should note that analyst opinions vary, with a consensus hold rating reflecting mixed views on the stock's potential.
Get Inspire Medical Systems, Inc. alerts
New 13F filings, insider trades, and analyst moves on $INSP, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.